Mapping the Molecular Landscape from Transient Ischemia to Reperfusion Injury in Cerebral Ischemia
Background
Stroke is the second leading cause of death worldwide and a major cause of adult disability. In clinical practice, three cerebral ischemic conditions—transient ischemic attack (TIA), ischemic stroke, and ischemia-reperfusion (IR) injury—have long been treated as separate entities. In particular, TIA has been classified as a 'benign' event due to the resolution of symptoms within 24 hours, and IR injury has often been considered a paradoxical adverse effect of therapeutic revascularization.
The problem is that the shared pathophysiological mechanisms and unique destructive pathways of these three conditions have not been systematically compared. A comprehensive understanding of how neuronal cell death patterns, glial activation patterns, and the degree of blood-brain barrier (BBB) damage differ is essential for developing precision treatment strategies tailored to the patient's condition. This review aims to fill this gap.
Key Findings
This review systematically compares the molecular, histological, and behavioral profiles of TIA, ischemic stroke, and IR injury.
TIA is not benign. Recent studies have shown that subtle neuronal and glial changes occur even after TIA. This means that potentially harmful changes can occur at the molecular level, even if imaging findings are normal. This provides evidence that TIA should be redefined as an active intervention target rather than a simple 'warning sign'.
Multilayered destruction of ischemic stroke. Ischemic stroke causes sustained hypoperfusion, infarction, BBB disruption, and a robust neuroinflammatory cascade. Neuronal cell death is temporally and spatially differentiated between necrosis and apoptosis, and the patterns of microglial and astrocyte activation also differ qualitatively from TIA.
The paradox of reperfusion. Although vascular recanalization is essential for rescuing ischemic tissue, IR injury paradoxically causes oxidative stress, cytokine release, and secondary infarction. Reperfusion itself activates new mechanisms of damage. The review integrates human brain imaging data and animal model histology to illustrate the differences in oxidative damage and BBB integrity in these three conditions.
The need for a precision medicine approach. The pathophysiology of each condition may vary depending on sex, age, and immune background, highlighting the limitations of a uniform treatment protocol. The review also points out the limitations of current experimental models in modeling comorbidities and chronic outcomes.
Significance and Prospects
The key message of this review is clear: TIA, ischemic stroke, and IR injury should be understood as a continuum of cerebral ischemia rather than separate diseases. This perspective will influence both the redefinition of diagnostic criteria and the individualization of treatment strategies.
Multimodal therapies, including pharmacological agents, stem cells, gene editing, and nanomedicine, are promising candidates, but clinical application is premature without rigorous preclinical and clinical validation. In particular, the translational gap from animal models to human disease remains a key challenge in this field. Precision medicine strategies that reflect sex, age, and immune profiles will be key to bridging this gap.
Transient ischemic attack (TIA), ischemic stroke, and ischemia-reperfusion (IR) injury represent a continuum of cerebrovascular disorders with distinct clinical and pathophysiological features. While TIA is classically considered benign, recent studies reveal subtle yet potentially deleterious neuronal and glial changes. Ischemic stroke typically results in sustained hypoperfusion, infarction, blood-brain barrier (BBB) disruption, and robust neuroinflammatory cascades. IR injury, though potentially beneficial through vessel recanalization, paradoxically induces oxidative stress, cytokine release, and secondary infarction. This review systematically compares the molecular, histological, and behavioral profiles of these three conditions. Key differences include patterns of neuronal death, glial activation, oxidative damage, and BBB integrity. Human neuroimaging data and animal model histology are integrated to illustrate characteristic features across the spectrum. We also discuss current experimental models and their translational relevance, highlighting challenges in modeling comorbidities and chronic outcomes. Precision medicine strategies considering sex, age, and immune background are emphasized as essential for advancing diagnostics and optimizing therapeutic efficacy. Emerging multimodal therapies, including pharmacological agents, stem cells, gene editing, and nanomedicine, hold promise but require rigorous validation. A deeper mechanistic understanding of each condition will be crucial for tailoring treatment strategies and bridging the translational gap in ischemic cerebrovascular disease.
In clinical practice, TIA patients often receive only follow-up observation after symptom resolution. The molecular-level evidence of potential damage presented in this review supports the introduction of active neuroprotective strategies after TIA. In acute stroke treatment, the need for adjunctive therapies to minimize IR injury during vascular recanalization is once again highlighted.
From a pharmaceutical and biotechnology perspective, the fact that each condition has different molecular targets is important. This allows for the development of pipelines for early intervention drugs for TIA, neuroinflammation inhibitors for ischemic stroke, and IR injury-specific antioxidant strategies. The use of nanomedicine-based drug delivery systems to achieve stage-specific targeted therapy by utilizing differences in BBB permeability is also noteworthy. However, these multimodal approaches are still in the preclinical stage, and considerable time and validation are required before they can be applied to actual patient treatment.